ArticleAntonie van Leeuwenhoek2026
Genomic, biological, and chemical studies of Streptomyces sp. LaBMicrA B280 isolated from the rhizosphere of Inga edulis Martius in the Amazon.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigated the taxonomic identity and biotechnological potential of the actinobacterium Streptomyces sp. LaBMicrA B280, isolated from the rhizosphere of Inga edulis (Mart.). Our approach combined a phylogenomic approach, annotation of metabolic subsystems and biosynthetic gene clusters (BGCs), biological assays to assess antifungal, antimalarial, cytotoxic, and larvicidal activities, classical molecular networking analysis, and characterization of the major compound in the most active fraction (FR3). The digital DNA-DNA hybridization values, using the d2 (GGDC) and d4 (TYGS) formulas, average nucleotide identity, and average amino acid identity (< 70% and ≤ 95-96%, respectively) revealed LaBMicrA B280 as a novel species within the Streptomyces genus. Our genomic analysis revealed 39 BGCs, including the cluster responsible for pentamycin biosynthesis, 314 metabolic subsystems, and 24 gene categories. In the molecular networking analysis, pentamycin was the only compound identified. Biological assays with fraction FR3 at a concentration of 50 µg/mL showed 96.59% ± 0.03 and 72.39% ± 0.18 inhibition against Plasmodium falciparum strains W2 and 3D7, respectively, as well as 91.45% ± 0.55 cytotoxicity against the HEp-2 cancer cell line. Larvicidal activity assays demonstrated 100% efficacy against Aedes aegypti (FO) at 250 µg/mL after 48 h. Pentamycin, a known antifungal compound, was successfully isolated from the highly active FR3 fraction. These findings highlight that LaBMicrA B280 exhibits a broad biotechnological potential and represents a promising source of important secondary metabolites for future application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.